메뉴 건너뛰기

대메뉴 건너뛰기 대메뉴 바로가기

Events

go to homeHOME  >  NEWS & EVENTS  >  EVENTS
[Seminar Notification] Dr. Dong Youn Hwang_04.20.2016
2016-04-11

1. Title : Generation and differentiation of human pluripotent stem cells for clinical applications

2. Speaker : Dong Youn Hwang, Ph.D

3. Affiliation : Associate Professor/Department of Medi-bio Science, CHA University, Korea

4. Date : 04. 20. 2016 16:00-17:00

5. Place : SIMS Main Building, Auditorium 109 (1F)

6. Abstract

Human pluripotent stem cells (hPSCs) which include human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPS cells) hold great promise for treating a variety of incurable diseases.

An efficient generation of xeno- and integration-free iPS cells is a prerequisite for clinical applications due to safety concerns. In addition somatic cells that can be obtained non-invasively from patients, such as urine cells, are useful cell sources for iPS cell generation.

We have established a xeno-free hPSC culture system to generate and expand therapeutically safe iPS cells. This culture system was found efficient in generating iPS cells from urine cells, let alone fibroblasts and adipose-derived stromal cells.

Furthermore, we recently established a cost-, time-, and labor-effective method of differentiating hPSCs (hESCs & iPS cells) into neural precursor cells (NPCs). Our method adopted 2-dimentional (2D) adherent differentiation system using a chemically defined and cost-effective medium. In addition the differentiation medium does not contain any animal-derived component, leading to generation of clinically compliant ‘xeno-free’ NPCs. Our detailed studies unveiled molecular mechanisms underpinning our 2D-based neural differentiation.

In summary, the xeno- and integration-free iPSCs derived from somatic cells are a promising cell source for future immune-compatible and clinically safe cell therapies. Furthermore, our novel method to generate NPCs from hPSCs would provide an important platform for clinical applications of hESCs and iPS cells to treating neurological diseases in the near future.